Metformin: Up to Date.
Antineoplastic Agents
/ therapeutic use
Diabetes Mellitus, Type 1
/ drug therapy
Diabetes Mellitus, Type 2
/ drug therapy
Female
Humans
Hyperglycemia
/ drug therapy
Hypoglycemic Agents
/ therapeutic use
Immunologic Factors
/ therapeutic use
Metformin
/ therapeutic use
Polycystic Ovary Syndrome
/ drug therapy
Metformin
heart failure
insulin resistance
polycystic ovary syndrome
type 1 diabetes
type 2 diabetes.
Journal
Endocrine, metabolic & immune disorders drug targets
ISSN: 2212-3873
Titre abrégé: Endocr Metab Immune Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269157
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
02
2019
revised:
22
04
2019
accepted:
23
04
2019
pubmed:
2
11
2019
medline:
20
11
2020
entrez:
1
11
2019
Statut:
ppublish
Résumé
Metformin is an oral hypoglycemic agent extensively used as first-line therapy for type 2 diabetes. It improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscles. Metformin improves insulin sensitivity and shows a beneficial effect on weight control. Besides its metabolic positive effects, Metformin has direct effects on inflammation and can have immunomodulatory and antineoplastic properties. The aim of this narrative review was to summarize the up-to-date evidence from the current literature about the metabolic and non-metabolic effects of Metformin. We reviewed the current literature dealing with different effects and properties of Metformin and current recommendations about the use of this drug. We identified keywords and MeSH terms in Pubmed and the terms Metformin and type 2 diabetes, type 1 diabetes, pregnancy, heart failure, PCOS, etc, were searched, selecting only significant original articles and review in English, in particular of the last five years. Even if many new effective hypoglycemic agents have been launched in the market in the last few years, Metformin would always keep a place in the treatment of type 2 diabetes and its comorbidities because of its multiple positive effects and low cost.
Sections du résumé
BACKGROUND
BACKGROUND
Metformin is an oral hypoglycemic agent extensively used as first-line therapy for type 2 diabetes. It improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscles. Metformin improves insulin sensitivity and shows a beneficial effect on weight control. Besides its metabolic positive effects, Metformin has direct effects on inflammation and can have immunomodulatory and antineoplastic properties.
AIM
OBJECTIVE
The aim of this narrative review was to summarize the up-to-date evidence from the current literature about the metabolic and non-metabolic effects of Metformin.
METHODS
METHODS
We reviewed the current literature dealing with different effects and properties of Metformin and current recommendations about the use of this drug. We identified keywords and MeSH terms in Pubmed and the terms Metformin and type 2 diabetes, type 1 diabetes, pregnancy, heart failure, PCOS, etc, were searched, selecting only significant original articles and review in English, in particular of the last five years.
CONCLUSION
CONCLUSIONS
Even if many new effective hypoglycemic agents have been launched in the market in the last few years, Metformin would always keep a place in the treatment of type 2 diabetes and its comorbidities because of its multiple positive effects and low cost.
Identifiants
pubmed: 31670618
pii: EMIDDT-EPUB-98407
doi: 10.2174/1871530319666190507125847
doi:
Substances chimiques
Antineoplastic Agents
0
Hypoglycemic Agents
0
Immunologic Factors
0
Metformin
9100L32L2N
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
172-181Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.